Nurix Therapeutics, Inc. 8-K

What Happened
Nurix Therapeutics, Inc. filed a Form 8‑K on January 12, 2026 under Regulation FD disclosing that it presented an overview of the company’s 2025 performance and major goals for 2026 at the 44th Annual J.P. Morgan Healthcare Conference. The filing attaches the company’s presentation materials and a related press release and notes that these materials are incorporated by reference.

Key Details

• Presentation date: January 12, 2026, at the 44th Annual J.P. Morgan Healthcare Conference.
• Presentation materials filed as Exhibit 99.1 and press release filed as Exhibit 99.2 to the Form 8‑K.
• Filing made under Item 7.01 (Regulation FD disclosure); no financial statements or earnings figures were included in this Form 8‑K.
• Form 8‑K signed by Christine Ring, Ph.D., J.D., Chief Legal Officer, dated January 12, 2026.

Why It Matters
This filing is a Regulation FD disclosure that makes Nurix’s investor presentation and press release publicly available—useful for investors wanting the company’s summary of 2025 results and strategic priorities for 2026. Because the 8‑K does not include new financial statements or detailed quarterly results, investors should review the attached presentation and press release for any operational updates or timeline changes and await formal filings for audited financial data.